» Authors » M Soltani

M Soltani

Explore the profile of M Soltani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 114
Citations 2559
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalantari S, Soltani M, Maghbooli M, Khoshe Mehr F, Kalantari Z, Borji S, et al.
Radiologia (Engl Ed) . 2025 Feb; 67(1):28-37. PMID: 39978877
Background: Cerebral small vessel ischemic disease (SVID) as a common age-related morbidity is the key mechanism of vascular cognitive impairment (VCI). This study uses Cerebral blood flow (CBF) measured by...
2.
Golzaryan A, Soltani M, Moradi Kashkooli F, Saboury B, Rahmim A
Sci Rep . 2025 Feb; 15(1):4052. PMID: 39901004
Each treatment cycle of radiopharmaceutical therapy (RPT) is administered as a single dose. We aimed to investigate a personalized metronomic RPT paradigm, employing multiple lower-dose administrations, to evaluate its effect...
3.
Razavi Z, Alizadeh S, Razavi F, Souri M, Soltani M
Int J Pharm . 2025 Jan; 670:125186. PMID: 39788400
The blood-brain barrier (BBB) plays a vital role in protecting the central nervous system (CNS) by preventing the entry of harmful pathogens from the bloodstream. However, this barrier also presents...
4.
Piranfar A, Moradi Kashkooli F, Zhan W, Bhandari A, Soltani M
Ann Biomed Eng . 2024 Nov; 53(3):562-577. PMID: 39570494
Purpose: In treating prostate cancer, distinguishing alpha and beta therapies is vital for efficient radiopharmaceutical delivery. Our study introduces a 3D image-based spatiotemporal computational model that utilizes MRI-derived images to...
5.
Souri M, Elahi S, Moradi Kashkooli F, Kohandel M, Soltani M
NPJ Syst Biol Appl . 2024 Nov; 10(1):136. PMID: 39567549
Intratumoral delivery and localized chemotherapy have demonstrated promise in tumor treatment; however, the rapid drainage of therapeutic agents from well-vascularized tumors limits their ability to achieve maximum therapeutic efficacy. Therefore,...
6.
Esmaeilion F, Soltani M, Taklifi A, Aliabadi A
Sci Rep . 2024 Sep; 14(1):21015. PMID: 39251617
Introducing suitable alternatives to the existing fossil fuels can provide insightful aspects of the expected benefits. In the energy sector, the transportation system is one of the key contributors to...
7.
Abazari M, Soltani M, Eydi F, Rahmim A, Moradi Kashkooli F
Biomed Phys Eng Express . 2024 Aug; 10(6). PMID: 39214120
F-Fluoromisonidazole (F-FMISO) is a highly promising positron emission tomography radiopharmaceutical for identifying hypoxic regions in solid tumors. This research employs spatiotemporal multi-scale mathematical modeling to explore how different levels of...
8.
Souri M, Golzaryan A, Soltani M
Eur J Pharm Biopharm . 2024 May; 199:114310. PMID: 38705311
Nanoparticle-based drug delivery systems hold potential in chemotherapy, but their limited accumulation in tumor tissues hinders effective drug concentration for combating tumor growth. Hence, altering the physicochemical properties of nanoparticles,...
9.
Piranfar A, Moradi Kashkooli F, Zhan W, Bhandari A, Saboury B, Rahmim A, et al.
NPJ Syst Biol Appl . 2024 Apr; 10(1):39. PMID: 38609421
Lutetium-177 prostate-specific membrane antigen (Lu-PSMA)-targeted radiopharmaceutical therapy is a clinically approved treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Even though common practice reluctantly follows "one size fits all"...
10.
Tehrani M, Moradi Kashkooli F, Soltani M
Comput Methods Programs Biomed . 2024 Mar; 247:108102. PMID: 38447317
Background And Objective: The effectiveness of current microwave ablation (MWA) therapies is limited. Administration of thermosensitive liposomes (TSLs) which release drugs in response to heat has presented a significant potential...